Research
Hormonal
Activation of PPARγ by synthetic thiazolidinediones (glitazones) improves insulin sensitivity and reduces blood glucose in type 2 diabetes, but carries significant cardiovascular risks (e.g., rosiglitazone) and side effects (weight gain, edema).
If prescribed a PPARγ agonist for diabetes, understand that while they improve insulin sensitivity, the specific drug matters. Pioglitazone may offer cardiovascular benefits, whereas rosiglitazone has been linked to increased heart risks. Discuss side effects like weight gain and edema with your doctor.
GoodQualifiesHIGH confidence
PPARγ is a regulator of lipid and glucose metabolism and therefore its synthetic ligands such as glitazones... improve insulin and glucose parameters and increase whole body insulin sensitivity... However, the influence of both thiazolidinediones on cardiovascular outcomes in patients with diabetes mellitus is different... rosiglitazone was associated with significant increases in myocardial infarction and death from cardiovascular causes.
Why this rating
Review of clinical trials (PROactive, FIELD, ACCORD) and mechanistic studies.
Source
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
Bogna Grygiel‐Górniak · Nutrition Journal · 2014
DOI 10.1186/1475-2891-13-17
narrative_reviewCited 1,191×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Activation of PPARα by omega-3 fatty acids (EPA/DHA) or synthetic fibrates increases fatty acid oxidation in metabolically active tissues (liver, heart, skeletal muscle), thereby lowering lipid levels and preventing hepatic steatosis.Good
- Activation of PPARβ/δ promotes fatty acid oxidation in skeletal and cardiac muscles, preventing obesity and protecting the heart from ischemia-reperfusion injury, particularly in the context of high-fat diets.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →